Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia

Experimental and Molecular Pathology

Volumn 92, Issue 1, 2012, Pages 13-19

  Tilli, T M ^a   Thuler, L C ^a,b   Matos, A R ^a   Coutinho Camillo, C M ^c   Soares, F A ^c,d   da Silva, E A ^e   Neves, A F ^f,g   Goulart, L R ^g   Gimba, E R ^a,h  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^f FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^g FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^h FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Diagnosis; Osteopontin; Prostate cancer; Splicing isoforms

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA SPLICING; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 80155135272     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.09.014     Document Type: Article

References (58)

1. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Pre- and post-translational regulation of osteopontin in cancer. Journal of Cell Communication and Signaling 2011, 5:111-122.
2. Andrew V., Lilja H., Ulmer D. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews 2008, 8:268-278.
3. Angelucci A., Festuccia C., D'Andrea G., Teti A., Bologna M. Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biological Chemistry 2002, 383:229-234.
4. Angelucci A., Festuccia C., Gravina G.L., Muzi P., Bonghi L., Vicentini C., Bologna M. Osteopontin enhances te cell proliferation induced bythe epidermal growth factor in human prostate cancer cells. The Prostate 2004, 59:157-166.
5. Arafat H., Lazar M., Salem K., Chipitsyna G., Gong Q., Pan T.C., Zhang R.Z., Yeo C.J., Chu M.L. Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery 2011, 150 (2):306-315.
6. Avgeris M., Stravodimos K., Scorilas A. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. The Prostate. 2011, 71:1780-1789.
7. Barry M.J., Fowler F.J., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K., Cockett A.T. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. The Journal of Urology 1992, 148:1549-1557.
8. Bidaux G., Flourakis M., Thebault S., Zholos A., Beck B., Gkika D., Roudbaraki M., Bonnal J.L., Mauroy B., Shuba Y., Skryma R., Prevarskaya N. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. The Journal of Clinical Investigation 2007, 117:1647-1657.
9. Blasberg J., Goparaju C.M., Pass H.I., Donington J.S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. Journal of Thoracic and Cardiovascular Surgery 2010, 139:1587-1593.
10. Blencowe B.J. Alternative splicing: new insights from global analyses. Cell 2006, 126:37-47.
11. Bostwick D.G. Grading prostate cancer. American Journal of Clinical Pathology 1994, 102(4 Suppl. 1):S38-S56.
12. Brooks J.D. Microarray analysis in prostate cancer research. Current Opinion in Urology 2002, 12:395-399.
13. Cao Y., Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prevention Research 2011, 4:486-501.
14. Chae S., Jun H.O., Lee E.G., Yang S.J., Lee D.C., Jung J.K., Park K.C., Yeom Y.I., Kim K.W. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. International Journal of Oncology 2009, 35:1409-1416.
15. Cho S.Y., Choi K., Jeon J.H., Kim C.W., Shin D.M., Lee J.B., Lee S.E., Kim C.S., Park J.S., Jeong E.M., Jang G.Y., Song K.Y., Kim I.G. Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer. Experimental & Molecular Medicine 2010, 42:310-318.
16. Courter D., Cao H., Kwok S., Kong C., Banh A., Kuo P., Bouley D.M., Vice C., Brustugun O.T., Denko N.C., Koong A.C., Giaccia A., Le Q.T. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 2010, 5(3):e9633.
17. Crawford H., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research 1998, 58:5206-5215.
18. Day J.R., Jost M., Reynolds M.A., Groskopf J., Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer Letters 2011, 301:1-6.
19. Durand X., Moutereau S., Xylinas E., de la Taille A. Progensa™ PCA3 test for prostate cancer. Expert Review of Molecular Diagnostics 2011, 11:137-144.
20. El Melegy N.T., Aboulella H.A., Abul-Fadl A.M., Mohamed N.A. Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer. British Journal of Biomedical Science 2010, 67:109-112.
21. Forootan S.S., Foster C.S., Aachi V.R., Adamson J., Smith P.H., Lin K., Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. International Journal of Cancer 2006, 118:2255-2261.
22. Goodison S., Urquidi V., Tarin D. CD44 cell adhesion molecules. Molecular Pathology 1999, 52:189-196.
23. Goparaju C.M., Pass H.I., Blasberg J.D., Hirsch N., Donington J.S. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. Journal of Thoracic Oncology 2010, 5:1516-1523.
24. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer. Oncogene 2006, 25:2192-2202.
25. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology 2004, 17:292-306.
26. Ivanov S., Ivanova A.V., Goparaju C.M., Chen Y., Beck A., Pass H.I. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochemical and Biophysical Research Communications 2009, 8:514-518.
27. Kelly K.A., Setlur S.R., Ross R., Anbazhagan R., Waterman P., Rubin M.A., Weissleder R. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Research 2008, 68:2286-2291.
28. Khodavirdi A.C., Song Z., Yang S., Zhong C., Wang S., Wu H., Pritchard C., Nelson P.S., Roy-Burman P. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Research 2006, 66:883-888.
29. Kiefer M., Bauer D.M., Barr P.J. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Research 1989, 17:3306.
30. Kon S., Maeda M., Segawa T., Hagiwara Y., Horikoshi Y., Chikuma S., Tanaka K., Rashid M.M., Inobe M., Chambers A.F., Uede T. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. Journal of Cellular Biochemistry 2000, 77:487-498.
31. Korbakis D., Gregorakis A.K., Scorilas A. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clinical Chemistry 2009, 55:904-913.
32. Kosari F., Asmann Y.W., Cheville J.C., Vasmatzis G. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2002, 11:1419-1426.
33. Kucur M., Isman F.K., Balci C., Onal B., Hacibekiroglu M., Ozkan F., Ozkan A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urologic Oncology 2008, 26:47-52.
34. Liu W., Gong J., Hu J., Hu T., Sun Y., Du J., Sun C., Guan M., Jiang H., Lu Y. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason Score. Urology 2011, 77:1006.e1-1006.e7.
35. Luco R.F., Misteli T. More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Current Opinion in Genetics & Development 2011, 21(4):366-372.
36. Mackinnon A.C., Yan B.C., Joseph L.J., Al-Ahmadie H.A. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Archives of Pathology & Laboratory Medicine 2009, 133:1033-1040.
37. McPherson S.J., Hussain S., Balanathan P., Hedwards S.L., Niranjan B., Grant M., Chandrasiri U.P., Toivanen R., Wang Y., Taylor R.A., Risbridger G.P. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of expression. International Journal of Oncology 2010, 38:1083-1091.
38. Mearini E., Cottini E., Cochetti G., Antognelli C., Talesa V. Biomarkers of prostate cancer. A review. Minerva Urologica e Nefrologica 2010, 62:163-178.
39. Mendes A., Scott R.J., Moscato P. Microarrays-identifying molecular portraits for prostate tumors with different Gleason patterns. Methods in Molecular Medicine 2008, 141:131-151.
40. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., Weber G.F. Osteopontin-c is a selective marker for breast cancer. International Journal of Cancer 2008, 122:889-897.
41. Mlcochová P., Barinka C., Tykvart J., Sácha P., Konvalinka J. Prostate-specific membrane antigen and its truncated form PSM'. The Prostate 2009, 69:471-479.
42. Ouyang B., Leung Y.K., Wang V., Chung E., Levin L., Bracken B., Cheng L., Ho S.M. α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology 2011, 77:249.e1-249.e7.
43. Pajares M., Ezponda T., Catena R., Calvo A., Pio R., Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. The Lancet Oncology 2007, 8:349-357.
44. Ramankulov A., Lein M., Kristiansen G., Loening S.A., Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. The Prostate 2007, 67:330-340.
45. Rigau M., Morote J., Mir M.C., Ballesteros C., Ortega I., Sanchez A., Colás E., Garcia M., Ruiz A., Abal M., Planas J., Reventós J., Doll A. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. The Prostate 2010, 70:1760-1767.
46. Rigau M., Ortega I., Mir M.C., Ballesteros C., Garcia M., Llauradó M., Colás E., Pedrola N., Montes M., Sequeiros T., Ertekin T., Majem B., Planas J., Ruiz A., Abal M., Sánchez A., Morote J., Reventós J., Doll A. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. The Prostate. 2011, 71:1736-1745.
47. Robertson B.W., Bonsal L., Chellaiah M.A. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Molecular Cancer 2010, 9:260-270.
48. Steiner I., Jung K., Schatz P., Horns T., Wittschieber D., Lein M., Dietel M., Erbersdobler A. Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology 2010, 77:260-266.
49. Sullivan J., Blair L., Alnajar A., Aziz T., Ng C.Y., Chipitsyna G., Gong Q., Witkiewicz A., Weber G.F., Denhardt D.T., Yeo C.J., Arafat H.A. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009, 146:232-240.
50. Tilli T.M., Franco V.F., Robbs B.K., Wanderley J.L., da Silva F.R., de Mello K.D., Viola J.P., Weber G.F., Gimba E.R. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Molecular Cancer Research 2011, 9:280-293.
51. Tilli, T.M., Mello, K.D., Accioly, M.T.S., Faria, P.A.S., Gimba, E.R.P., 2011b. OPNc and OPNb splicing isoforms activate prostate cancer progression features through PI3K signaling pathway. Unpublished results.
52. Troyer D.A., Mubiru J., Leach R.J., Naylor S.L. Promise and challenge: markers of prostate cancer detection, diagnosis and prognosis. Disease Markers 2004, 20:117-128.
53. Wang P., Guo Y.M., Liu M., Qiang Y.Q., Guo X.J., Zhang Y.L., Duan X.Y., Zhang Q.J., Liang W. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean Journal of Radiology 2008, 9:432-438.
54. Weber G.F., Lett G.S., Haubein N.C. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncology Reports 2011, 25:433-441.
55. Yan W., Qian C., Zhao P., Zhang J., Shi L., Qian J., Liu N., Fu Z., Kang C., Pu P., You Y. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro-Oncology 2010, 12:765-775.
56. You J., Cozzi P., Walsh B., Willcox M., Kearsley J., Russell P., Li Y. Innovative biomarkers for prostate cancer early diagnosis and progression. Critical Reviews in Oncology/Hematology 2010, 73:10-22.
57. Young M., Kerr J.M., Termine J.D., Wewer U.M., Wang M.G., McBride O.W., Fisher L.W. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990, 7:491-502.
58. Zhang Y., Forootan S.S., Kamalian L., Bao Z.Z., Malki M.I., Foster C.S., Ke Y. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. International Journal of Oncology 2011, 38:1083-1091.